Search





Search





Markets
/
Stocks
/
nasdaq-jazz
/

Jazz Pharmaceuticals PLC

JAZZ

Add to Watchlist

225.790USD

-1.170-0.52%

Close 05/08, 16:00（ET）Quotes delayed by 15 min

13.71BMarket Cap

547.58P/E TTM



Jazz Pharmaceuticals PLC

225.790

-1.170-0.52%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Jazz Pharmaceuticals PLC

Currency: USD Updated: 2026-05-08

Key Insights

Jazz Pharmaceuticals PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 2 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 226.26.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Jazz Pharmaceuticals PLC's Score

Industry at a Glance

Industry Ranking

2 / 156

Overall Ranking

9 / 4494

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Jazz Pharmaceuticals PLC Highlights

StrengthsRisks

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Overvalued

The company’s latest PE is 547.58, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 64.33M shares, decreasing 8.94% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 12.93K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.17.

Analyst Rating

Based on 17 analysts

Buy

Current Rating

226.261

Target Price

+8.75%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-08

The current financial score of Jazz Pharmaceuticals PLC is 8.66, ranking 32 out of 156 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 1.07B, representing a year-over-year increase of 19.05%, while its net profit experienced a year-over-year increase of 416.72%.

Score

Industry at a Glance

Previous score

8.66

Change



Financials

6.52

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.20

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.96

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.60

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Jazz Pharmaceuticals PLC's Company Valuation

Currency: USD Updated: 2026-05-08

The current valuation score of Jazz Pharmaceuticals PLC is 8.69, ranking 9 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is 547.58, which is 0.52% below the recent high of 550.42 and 118.43% above the recent low of -100.94.

Score

Industry at a Glance

Previous score

8.69

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 2/156

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-08

The current earnings forecast score of Jazz Pharmaceuticals PLC is 8.56, ranking 29 out of 156 in the Pharmaceuticals industry. The average price target is 210.00, with a high of 247.00 and a low of 147.00.

Score

Industry at a Glance

Previous score

8.56

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 17 analysts

Buy

Current Rating

226.261

Target Price

+8.75%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Jazz Pharmaceuticals PLC

JAZZ

Amgen Inc

AMGN

Biogen Inc

BIIB

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

Vertex Pharmaceuticals Inc

VRTX

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-08

The current price momentum score of Jazz Pharmaceuticals PLC is 9.54, ranking 8 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 239.73 and the support level at 202.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.67

Change

-0.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

4.654

Buy

RSI(14)

73.023

Buy

STOCH(KDJ)(9,3,3)

88.097

Overbought

ATR(14)

6.587

High Vlolatility

CCI(14)

146.958

Buy

Williams %R

12.939

Overbought

TRIX(12,20)

0.508

Sell

StochRSI(14)

68.771

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

220.328

Buy

MA10

211.250

Buy

MA20

205.496

Buy

MA50

193.900

Buy

MA100

181.409

Buy

MA200

159.032

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Jazz Pharmaceuticals PLC is 10.00, ranking 1 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 102.54%, representing a quarter-over-quarter decrease of 0.76%. The largest institutional shareholder is The Vanguard, holding a total of 5.81M shares, representing 9.27% of shares outstanding, with 4.71% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

5.89M

+0.17%

BlackRock Institutional Trust Company, N.A.

4.96M

-1.01%

Capital World Investors

2.67M

+4.37%

LSV Asset Management

2.46M

-2.23%

Dimensional Fund Advisors, L.P.

2.62M

-7.52%

State Street Investment Management (US)

1.84M

-1.61%

Franklin Advisers, Inc.

1.81M

+164.20%

EcoR1 Capital, LLC

1.71M

Fuller & Thaler Asset Management Inc.

1.68M

+3.14%

Columbia Threadneedle Investments (US)

1.29M

-17.98%

Risk Assessment

Currency: USD Updated: 2026-05-08

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Jazz Pharmaceuticals PLC is 7.07, ranking 44 out of 156 in the Pharmaceuticals industry. The company's beta value is 0.29. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Jazz Pharmaceuticals PLC’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.